Vol. 23/No. 18 | OncologyLive

EphrinB2 Emerges as Targetable Option in Urothelial Carcinoma

September 20, 2022


Treatment with soluble EphB4-human serum albumin plus pembrolizumab elicited synergistic activity and an improved overall survival and objective response rate compared with historical data for PD-1/PD-L1 monotherapy in patients with platinum-refractory metastatic urothelial carcinoma.

Changes Improve Radiation Therapy in SCLC

September 16, 2022

Investigators are making progress in delineating the optimal use of radiation therapy for the treatment of patients with small cell lung cancer, which remains a cornerstone of therapy for the malignancy, particularly in limited-stage disease.

Progress on New Therapies Stirs Hope in SCLC

September 15, 2022


During the past 15 years, breakthrough discoveries have revolutionized the treatment landscape for most patients with lung cancer, progress that has helped fuel an overall drop in cancer mortality.